HUTCHMED (China) (HCM) Operating Leases (2019 - 2025)

HUTCHMED (China) (HCM) posted quarterly Operating Leases of $1.9 million for Q4 2025, down 40.43% quarter-over-quarter from $3.1 million in Q2 2025.

HUTCHMED (China) (HCM) Operating Leases (2019 - 2025) Analysis & Trends

HUTCHMED (China) (HCM) has reported Operating Leases for 5 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.

In Q4 2025, Operating Leases changed N/A year-over-year to $1.9 million; the TTM figure through Dec 2025 stood at $1.9 million (changed N/A YoY), while the FY2025 annual figure was $1.9 million, changed N/A from the prior year.
Operating Leases declined to $1.9 million in Q4 2025 per HCM's latest filing, from $3.1 million in the prior quarter.
Across five years, Operating Leases topped out at $7.2 million in Q4 2021 and bottomed at $1.9 million in Q4 2025.
Historically, Operating Leases has averaged $4.7 million across 3 years, with a median of $5.2 million in 2022.
Annual changes were most pronounced in 2021 — Operating Leases soared 81.73% — and 2022, when it fell 27.44%.
HUTCHMED (China)'s Operating Leases stood at $7.2 million in 2021, then slipped by 27.44% to $5.2 million in 2022, then plunged by 64.36% to $1.9 million in 2025.
Business Quant data shows HCM's Operating Leases at $1.9 million in Q4 2025, $3.1 million in Q2 2025, and $5.2 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	HUTCHMED (China)	2.18 Bn	2.18 Bn	-

Download Data